TY - JOUR
T1 - Comparison of fixed dose versus train-of-four titration of cisatracurium in acute respiratory distress syndrome
AU - Thompson Bastin, Melissa L.
AU - Smith, Rebecca R.
AU - Bissell, Brittany D.
AU - Wolf, Heather N.
AU - Wiegand, Alexandra M.
AU - Cavagnini, Megan E.
AU - Ahmad, Yahya
AU - Flannery, Alexander H.
N1 - Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/10
Y1 - 2021/10
N2 - Purpose: To compare the ventilatory and clinical outcomes associated with a fixed-dose cisatracurium infusion versus a titrated infusion strategy in patients with Acute Respiratory Distress Syndrome (ARDS). Materials and methods: Single-center, retrospective, cohort study in a medical ICU of a tertiary care academic medical center. Adult patients ≥18 years old with a continuous infusion of cisatracurium for ≥12 h for treatment of ARDS were included. The primary outcome was the PaO2 /FiO2 ratio assessed at 24 and 48 h following cisatracurium initiation. Secondary outcomes included amount of average dose of drug administered, 28-day ventilator-free days, LOS, and hospital mortality. Results: 167 patients were included; median baseline PaO2/FiO2 was 97 (76–146), median SOFA score of 9 (7–11), and ICU mortality was 71/167 (43%). In a mixed-effects model, fixed dose and titrated cisatracurium associated with similar changes in PaO2/FiO2 assessed at 24 and 48 h (p = 0.316). Fixed-dose was associated with a >3-fold increase in drug exposure (average dose 6.4 (5.4–8.0) vs. 2.0 (1.5–2.8) mcg/kg/min; p < 0.001, respectively). No differences were observed in secondary clinical endpoints. Conclusion: Fixed-dose cisatracurium was associated with similar ventilatory and clinical outcomes compared to titrated strategy, yet it was associated with a 3-fold increase in dose administered.
AB - Purpose: To compare the ventilatory and clinical outcomes associated with a fixed-dose cisatracurium infusion versus a titrated infusion strategy in patients with Acute Respiratory Distress Syndrome (ARDS). Materials and methods: Single-center, retrospective, cohort study in a medical ICU of a tertiary care academic medical center. Adult patients ≥18 years old with a continuous infusion of cisatracurium for ≥12 h for treatment of ARDS were included. The primary outcome was the PaO2 /FiO2 ratio assessed at 24 and 48 h following cisatracurium initiation. Secondary outcomes included amount of average dose of drug administered, 28-day ventilator-free days, LOS, and hospital mortality. Results: 167 patients were included; median baseline PaO2/FiO2 was 97 (76–146), median SOFA score of 9 (7–11), and ICU mortality was 71/167 (43%). In a mixed-effects model, fixed dose and titrated cisatracurium associated with similar changes in PaO2/FiO2 assessed at 24 and 48 h (p = 0.316). Fixed-dose was associated with a >3-fold increase in drug exposure (average dose 6.4 (5.4–8.0) vs. 2.0 (1.5–2.8) mcg/kg/min; p < 0.001, respectively). No differences were observed in secondary clinical endpoints. Conclusion: Fixed-dose cisatracurium was associated with similar ventilatory and clinical outcomes compared to titrated strategy, yet it was associated with a 3-fold increase in dose administered.
KW - ARDS
KW - Cisatracurium
KW - Critical illness
KW - Neuromuscular blockade
KW - Paralysis
KW - Respiratory distress syndrome
UR - http://www.scopus.com/inward/record.url?scp=85108091986&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108091986&partnerID=8YFLogxK
U2 - 10.1016/j.jcrc.2021.05.011
DO - 10.1016/j.jcrc.2021.05.011
M3 - Article
C2 - 34118504
AN - SCOPUS:85108091986
SN - 0883-9441
VL - 65
SP - 86
EP - 90
JO - Journal of Critical Care
JF - Journal of Critical Care
ER -